Want to see JP:4881 full AI Analyst Report?

FunPep Company Limited (4881) Price & Analysis

0 Followers

4881 Stock Chart & Stats

¥79.00

¥1.00(0.72%)

At close: Jan 08 4:00 PM EST

¥79.00

¥1.00(0.72%)

Day’s Range― - ―

52-Week Range¥45.00 - ¥130.00

Previous CloseN/A

Volume532.20K

Average Volume (3M)200.19K

Market Cap

¥2.43B

Enterprise Value¥1.10K

Total Cash (Recent Filing)¥1.89B

Total Debt (Recent Filing)¥0.00

Price to Earnings (P/E)―

Beta0.69

Next Earnings

Nov 18, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-38.10

Shares Outstanding50,666,700

10 Day Avg. Volume121,960

30 Day Avg. Volume200,190

Financial Highlights & Ratios

PEG Ratio-0.03

Price to Book (P/B)2.13

Price to Sales (P/S)9943.96

P/FCF Ratio-2.25

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-19.9

Revenue Forecast (FY)¥300.00M

Bulls Say, Bears Say

Bulls Say

Debt-Free Balance SheetA debt-free structure limits refinancing and interest burdens, giving this early-stage biotech greater financial flexibility than a leveraged peer. This advantage is meaningful even though sustained losses continue to erode shareholder equity.

Prior Revenue GrowthRevenue growth in 2024 shows the company has previously demonstrated some ability to expand commercial or development-related receipts. However, the subsequent 2025 collapse materially weakens confidence that this improvement represents a durable growth trend.

Earlier Cash Flow ImprovementImprovement in free cash flow during 2023 and 2024 indicates that cash consumption had briefly moderated before the latest deterioration. This provides limited evidence of potential cost or investment control, although 2025 results show the benefit was not sustained.

Bears Say

Revenue CollapseA roughly 94% revenue decline signals severe commercial volatility and weak operating visibility. Such a contraction can impair development funding, reduce negotiating power with partners, and make future revenue recovery dependent on uncertain product or pipeline progress.

Deepening LossesPersistent unprofitability, negative gross profit, and a more than doubling net loss indicate that the current business model is not covering its cost base. Continued losses may constrain investment capacity and increase reliance on external capital over the medium term.

Accelerating Cash BurnAccelerating operating cash burn and consistently negative free cash flow show that the company is not self-funding. Combined with declining equity, this raises ongoing financing and dilution risk even without debt, potentially limiting strategic flexibility.

4881 FAQ

What was FunPep Company Limited’s price range in the past 12 months?

FunPep Company Limited lowest stock price was ¥45.00 and its highest was ¥130.00 in the past 12 months.

What is FunPep Company Limited’s market cap?

FunPep Company Limited’s market cap is ¥2.43B.

When is FunPep Company Limited’s upcoming earnings report date?

FunPep Company Limited’s upcoming earnings report date is Nov 18, 2026 which is in 48 days.

How were FunPep Company Limited’s earnings last quarter?

FunPep Company Limited released its earnings results on Aug 14, 2026. The company reported -¥5.63 earnings per share for the quarter.

Is FunPep Company Limited overvalued?

According to Wall Street analysts FunPep Company Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does FunPep Company Limited pay dividends?

FunPep Company Limited does not currently pay dividends.

What is FunPep Company Limited’s EPS estimate?

FunPep Company Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does FunPep Company Limited have?

FunPep Company Limited has 50,666,700 shares outstanding.

What happened to FunPep Company Limited’s price movement after its last earnings report?

FunPep Company Limited reported an EPS of -¥5.63 in its last earnings report. Following the earnings report the stock price went up 2.041%.

Which hedge fund is a major shareholder of FunPep Company Limited?

Currently, no hedge funds are holding shares in JP:4881

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

FunPep Company Limited

FunPep Company Limited specializes in the discovery and advancement of pharmaceutical drugs, functional cosmetics, and medical devices, leveraging its core technology in functional peptides. The company's development pipeline prominently features SR-0379, a functional peptide designed to address skin ulcers. FunPep is advancing FPP003, an antibody-inducing peptide, which is undergoing Phase II clinical trials for psoriasis in Australia and for ankylosing spondylitis in Japan. Another antibody-inducing peptide, FPP004X, is also in development, targeting pollinosis. Additionally, the company is working on FPP006, a corona peptide vaccine, and FPP005, an antibody-inducing peptide for psoriasis. Established in 2013, FunPep Company Limited operates from its headquarters in Tokyo, Japan.